1. Modulation of P-Glycoprotein at the Blood-BrainBarrier: Opportunities to Improve Central Nervous System Pharmacotherapy. Vol 60, No. 2. Miller et al.

(1)

66

BIBLIOGRAFIA

1. Modulation of P-Glycoprotein at the Blood-BrainBarrier: Opportunities to Improve Central Nervous System Pharmacotherapy. Vol 60, No. 2. Miller et al.

2. How can we best use structural information on P-glycoprotein to design inhibitors? . C.A. McDevitt, R. Callaghan / Pharmacology & Therapeutics 113 (2007) 429–441.

3. K. Hollenstein, R.J. Dawson, K.P. Locher, Curr. Opin. Struct. Biol.;

2007, 17, 412–418.

4. Nicola Antonio Colabufo, Francesco Berardi, Mariangela Cantore, Marialessandra Contino, Carmela Inglese, Mauro Niso, and Roberto Perrone -Perspectives of P-Glycoprotein Modulating Agents in Oncology and Ne rodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Pote tials -J. Med. Chem. 2010, 53, 1883–1897 DOI: 10.1021/jm900743c.

5. Avenda~no, C.; Men_endez, J. C. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem. 2002, 9, 159–193.

6. Callaghan, R.; Ford, R. C.; Kerr, I. D. The translocation mechanism of P- glycoprotein. FEBS Lett. 2006, 580, 1056–1063.

7. Constantinides, P. P.; Wasan, K. M. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J. Pharm. Sci. 2007, 96, 235–

248. 8. Bradshaw D.M., Arceci R.J., Clinical relevance of transmembrane drug

efflux as a mechanism of multidrug resistance, J. Clin. Oncol. (1998), 3674-

3690.

(2)

67 9. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm.

Res. 2007, 24, 1745.

10. Benet, L. Z.; Izumi, T.; Zhang, Y.; Silverman, J. A.; Wacher, V. J.

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Controlled Release 1999, 62, 25–31.

11. Custodio, J. M.; Wu, C.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Delivery Rev. 2008, 60, 717–733.

12. Mohri, K.; Uesawa, Y. Enzymatic activities in the microsomes prepared from rat small intestinal epithelial cells by differential procedures. Pharm.

Res. 2001, 18, 1232–1236.

13. Radiosynthesis and in vivo evaluation of [

¹¹

C] MC80 for P-glycoprotein imaging. Bioorganic & medicinal Chemistry 18 (2010) 6489.6495.

14. Avoiding Barriers to PET Radioligand Development: Cellular Assays of Brain Efflux Transporters. THE JOURNAL OF NUCLEAR MEDICINE Vol. 52 No. 3 March 2011.

15. 2-[(3-Methoxyphenylethyl)phenoxy]-Based ABCB1 Inhibitors: Effect of Different Basic Side-Chains on Their Biological Properties. Nicola Antonio Colabufo, Francesco Berardi, Roberto Perrone, Simona Rapposelli, Maria Digiacomo, Michael Vanni, and Aldo Balsamo. J. Med. Chem. 2008, 51, 7602–7613.

16. Klopman, G.; Shi, L. M. and Ramu, A.; Mol. Pharmacol.; 1997, 52, 323-

334.

(3)

68 17. Wolfgang Lösher, Heidrun Potshka ,Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Progress in Neurobiology 76, (2005) , 22-76.

18. Audus KL.; Eur J Pharm Sci, 1999, 8 (3),161–5.

19. Pacifici GM, Nottoli R.; Clin Pharmacokinet.; 1995, 28 (3), 235–69.

20. Fromm M.F. et al., The influence of MDR1 polymorphisms on P- glycoprotein espression and function in humans, Adv. Drug Deliv. Rev.

(2002), 54, 1295-1310.

21. Bartels, A. L.; Willemsen, A. T. M.; Kortekaas, R.; de Jong, B. M.; de Vries, R.; de Klerk, O.; van Oostrom, J. C. H.; Portman, A.; Leenders, K. L.

Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J. Neural. Transm. 2008, 115, 1001- 1009.

22. Vogelgesang, S.; Cascorbi, I.; Kroemer, H. K.; Schroeder, E.; Pahnke, J.; Siegmund, W.; Keil, C.; Warzok, R. W.; Walker, L. C. Deposition of amyloid is inversely correlated with the expression of P-glycoprotein- implications on the possibility of prevention of Alzheimer’s disease. Acta Neuropathol. 2001, 102, 545.

23. Fernandez, C.; Buyse, M.; German-Fattal, M.; Gimenez, F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci. 2004, 7, 359- 371.

24. Mcrae, M. P.; Brouwer, K. L. R.; Kashuba, A. D. M. Cytokine regulation of P-glycoprotein. Drug Metab. Rev. 2003, 35, 19-33.

25. Alafuzoff, I.; Iqbal, K.; Friden, H.; Adolfsson, R.; Winblad, B.Histopathological criteria for progressive dementia disorders: clinical- pathological correlation and classification by multivariate data analysis.

Acta Neuropathol. 1987, 74, 209-225.

(4)

69 26. Arriagada, P.V.; Marzloff, K.; Hyman, B.T. Distribution of Alzheimer- type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42, 1681-1688.

27. Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne,G.; Cutler,L.;

Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.;

Gonzalez, M. I.; Dingwall, C.; Redshaw, A. M. S.; Davis, J. B. Oral administration of a potent and selective nonpeptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. Journal of Neurochemistry 2007, 100, 802-809.

28. Meredith, Jr. J. E.; Thompson, L. A.; Toyn, J. H.; Marcin, L.; Barten, D.

M.; Marcinkeviciene, J.; Kopcho, L.; Kim, Y.; Lin, A.; Guss, V.; Burton, C.; Iben, L.; Polson, C.; Cantone, J.; Ford, M.; Drexler, D.; Fiedler, T.;

Lentz, K. A.; Grace, Jr. J. E.; Kolb, J.; Corsa, J.; Pierdomenico, M.; Jones, K.; Olson, R. E.; Macor, J. E.; Albright, C. F. P-glycoprotein efflux and other factors limit brain amyloid reduction by β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J. Pharmacol. Exp. Ther.

2008, 326, 502-513.

29. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H.

K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W.

Deposition of Alzheimer’s �-amyloid is inversely correlated with P- glycoprotein expression in the brains of elderly nondemented humans.

Pharmacogenetics 2002, 12, 535-541.

30. Vogelgesang, S.; Kuhnke, D.; Jedlitschky, G.; Jucker, M.; Mosyagin, I.;

Pahnke, J.; Cascorbi, I.; Kroemer, H. K.; Walker, L. C.; Warzok, R. W. P- glycoprotein (ABCB1) mediates transport of Alzheimer’s beta-amyloid peptides. Acta Neuropathol. 2006, 112, 365-367.

31. Schapira, A. H. Etiology of Parkinson’s disease. Neurobiology 2006, 66,

S10-23.

(5)

70 32. Wood-Kaczmar, A.; Gandhi, S.; Wood, N. W. Understanding the molecular causes of Parkinson’s disease. Trends Mol. Med. 2006, 12, 521- 528.

33. Bain, L. J.; LeBlanc, G. A. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol. Appl.

Pharmacol. 1996, 141, 288-298.

34. Rajput, A.H. Environmental toxins accelerate Parkinson’s disease onset.

Neurology 2001, 56, 4-5.

35. Martel, F.; Calhau, C.; Soares-da-Silva, P.; Azevedo, I. Transport of [H- 3]MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4). NaunynSchmiedebergs Arch. Pharmacol. 2001, 363, 1-10.

36. Uversky, V. N.; Li, J.; Fink, A. L. Metal-triggered structural transformations, aggregation, and fiblillation of human α- synuclein. J. Biol.

Chem. 2001, 276, 44284-44296.

37. Di Monte, D. A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol.

2003, 2, 531-538.

38. Bartels, A. L.; Kortekaas, R.; Bart, J.; Willemsen, A. T. M.; de Klerk, O.

L.; de Vries, J. J.; van Oostrom, J. C. H.; Leenders, K. L. Neurobiol. Aging.

2008, doi:10.1016/j.neurobiolaging. 2008.02.002.

39. Regesta, G.; Tanganelli, P. Clinical aspects and biological bases of drug- resistant epilepsies. Epilepsy Res. 1999, 34, 109-122.

40. Yang, Z. H.; Liu, X. D. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.

Epilepsy Res. 2008, 78, 40-49.

(6)

71 41. Luna-Tortós, C.; Fedrowitz, M.; Löscher, W. Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 2008, 55, 81364-1375.

42. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.;

Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P- glycoprotein. Neuropharmacol. 2007, 52, 333-346.

43. Bauer, B.; Hartz, A. M.; Pekcec, A.; Toellner, K.; Miller, D. S.;

Potschka, H. Seizure-induced up-regulation of P-glycoprotein at the blood- brain barrier through glutamate and cyclooxygenase-2 signaling. Mol.

Pharmacol. 2008, 73, 1444-1453.

44. Kwan, P.; Brodie, M. J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46, 224-235.

45. Löscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76, 22-76.

46. Löscher, W. Mechanisms of drug resistance Epileptic Disord. 2005, 7 (Suppl. 1), S3-S9.

47. van Vliet, E. A.; van Schaik, R.; Edelbroek, P. M.; Redeker, S.; Aronica, E.; Wadman, W. J.; Marchi, N.; Vezzani, A.; Gorter, J. A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin- treated chronic epileptic rats. Epilepsia 2006, 47, 672-680.

48. van Dellen, A.; Grote, H. E.; Hannan, A. J. Gene-environment

interactions, neuronal dysfunction and pathological plasticity in

Huntington's disease. Clin. Exp. Pharmacol. Physiol. 2005, 32, 1007-1019.

(7)

72 49. Arrasate, M.; Mitra, S.; Schweitzer, E. S.; Segal, M. R.; Finkbeiner, S.

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 14, 805-810.

50. Patassini, S.; Giampà, C.; Martorana, A.; Bernardi, G.; Fusco, F. R.

Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci. Lett.

2008, 448, 166-169.

51. Vogelgesang, S.; Glatzel, M.; Walker, L. C.; Kroemer, H. K.; Aguzzi, A.; Warzok, R. W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol. 2006, 111, 436-443.

52. Armstrong, R. A.; Lantos, P. L.; Cairns, N. J. The spatial patterns of prion protein deposits in Creutzfeldt-Jakob disease: comparison with beta- amyloid deposits in Alzheimer’s disease. Neurosci. Lett. 2001, 298, 53-56.

53. Vogelgesang, S.; Warzok, R. W.; Cascorbi, I.; Kunert-Keil, C.;

Schroeder, E.; Kroemer, H. K.; Siegmund, W.; Walker, L. C.; Pahnke, J.

The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 2004, 1, 121-125.

54. Mulder, D. W. Clinical limits of amyotrophic lateral sclerosis Adv.

Neurol. 1982, 36, 15-22.

55. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N.

Engl. J. Med. 1994, 330, 585-591.

(8)

73 56. Kriz, J.; Gowing, G.; Julien, J. P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 2003, 53, 429-436.

57. Kirkinezos, I. G.; Hernandez, D.; Bradley, W. G.; Moraes, C. T. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem. 2004, 88, 821-826.

58. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.;

Callaghan, R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 2000, 39, 11901–

11906.

59. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.;

Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein.

60. How can we best use structural information on P-glycoprotein to design inhibitors? . C.A. McDevitt, R. Callaghan / Pharmacology & Therapeutics 113 (2007) 429–441.

61. Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials Nicola Antonio Colabufo,* Francesco Berardi, Mariangela Cantore, Marialessandra Contino, Carmela Inglese, Mauro Niso, and Roberto Perrone J. Med. Chem. 2010, 53, 1883–1897 1883.

62. Krishna, R.; Mayer, L. D. Multidrug resistance(MDR) in cancer.

Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J.

Pharm. Sci. 2000, 11, 265–283.

(9)

74 63. Stupp, R.; Bauer, J.; Pagani, O.; Gerard, B.; Cerny, T.; Sessa, C.;

Bastian, G.; Sarkany, M.; Schlapfer, J.; Giroux, B.; Leyvraz, S. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR- modulator S9788 in a phase I trial. Ann. Oncol. 1998, 9, 1233–1242.

64. Wandel, C.; Kim, R. B.; Kajiji, S.; Guengerich, P.; Wilkinson, G. R.;

Wood, A. J.P-glycoprotein and cytochrome P-450 3A inhibition:

dissociation of inhibitory potencies. Cancer Res. 1999, 59, 3944–3948.

65. Nicola Antonio Colabufo, Francesco Berardi, Mariangela Cantore, Marialessandra Contino, Carmela Inglese, Mauro Niso, and Roberto Perrone, Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials - J. Med. Chem. (2010), 53, 1883–1897.

66. Dantzig A.H., Curr. Med. Chem., (2001), 39.

67. Mistry P., Cancer Res., (2001), 749.

68. Martin C., Br. J., Pharmacol., (1999), 403.

69. Sikic B.J., Modulation of multidrug resistance: a paradigm for translational clinical research, (1999), 183.

70. Fischer V., The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A4, (1998), 802.

71. Radiosynthesis and in vivo evaluation of [

¹¹

C] MC80 for P-glycoprotein imaging. Bioorganic & medicinal Chemistry 18 (2010) 6489.6495.

72. Avoiding Barriers to PET Radioligand Development: Cellular Assays of

Brain Efflux Transporters. THE JOURNAL OF NUCLEAR MEDICINE

Vol. 52 No. 3 March 2011.

(10)

75 73. 2-[(3-Methoxyphenylethyl)phenoxy]-Based ABCB1 Inhibitors: Effect of Different Basic Side-Chains on Their Biological Properties. Nicola Antonio Colabufo, Francesco Berardi, Roberto Perrone, Simona Rapposelli, Maria Digiacomo, Michael Vanni, and Aldo Balsamo. J. Med. Chem. 2008, 51, 7602–7613.

74. Synthesis and Biological Evaluation of (Hetero)Arylmethyloxy- and Arylmethylamine-phenyl. Derivatives as Potent P-glycoprotein Modulating Agents. Nicola Antonio Colabufo,*, Francesco Berardi,† Roberto Perrone,†

SimonaRapposelli,*, Maria Digiacomo, Michael Vanni,‡ and Aldo Balsamo. J. Med. Chem. 2008, 51, 1415–1422.

75. Arylmethyloxyphenyl Derivatives: Small Molecules Displaying P-

Glycoprotein Inhibition. Nicola Antonio Colabufo,*, Francesco Berardi

Roberto Perrone, Simona Rapposelli,*, Maria Digiacomo, and Aldo

Balsamo. J. Med. Chem. 2006, 49, 6607- 6613.